MAP3K8 and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, acquired chemotherapy resistance in response to imatinib in chronic myeloid leukemia model as well as RAF inhibitors chemoresistance in B-RAFV600E melanoma cells was associated with increased TPL2-induced inflammation, highlighting the importance of TPL2 in therapy-induced inflammation and chemoresistance 125, 126.